Recordati says 2025 profit to be hit by weak economy, currency impact

Recordati Industria Chimica E Farmaceutica SpA

12/11/2025 07:38

Nov 12 (Reuters) - Italian drug maker Recordati RECI.MI said late on Tuesday that its core profit for 2025 would come in at the lower end of its expectations, citing challenging economic conditions and negative currency effects.

The company had forecast in February that its earnings before interest, taxes, depreciation and amortization (EBITDA) would in a range between 970 million and 1 billion euros ($1.13-$1.17 billion).

The company's nine-month EBITDA rose 11.8% to 743.9 million euros boosted by a 12.2% rise in revenue.

The result was partially offset by a higher level of investments to support the launch of its hypercortisolemia drug Isturisa's additional use in the U.S., and to back its geographic expansion.

Currency movements had a 2% negative impact on its revenue in the January-September period, and that was expected to increase to 3% for the full year, it said.

Recordati expects its rare diseases business unit to approach 50% of total revenues in 2026. It reaffirmed its 2027 targets presented in a business plan in April.

The company will pay an interim dividend of 0.63 euros per share for 2025, it said.

($1 = 0.8575 euros)

 (Reporting by Romolo Tosiani; Editing by Anna Pruchnicka)

 ((romolo.tosiani@thomsonreuters.com))